Calando Doses First Patient in Phase I Cancer Study
Posted on: Monday, 2 June 2008, 12:22 CDT
Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has announced that the first patient has successfully completed the first dosing cycle of CALAA-01 in the first clinical trial using systemically-delivered siRNA to treat cancer.
This open-label, dose-escalation Phase I study in patients with solid tumors which are refractory to standard-of-care therapies is being conducted at the UCLA Jonsson Cancer Center in Los Angeles, California, and at South Texas Accelerated Research Therapeutics in San Antonio, Texas.
CALAA-01 is a targeted nanoparticle, comprised of a proprietary, non-chemically-modified siRNA against the M2 subunit of ribonucleotide reductase - a clinically-validated cancer target - formulated with Calando's proprietary RONDEL (RNAi/Oligonucleotide Nanoparticle Delivery) polymer delivery system.
Jeremy Heidel, Calando CSO for siRNA delivery, said: "We look forward to the continued treatment of this patient and subsequent patients and the establishment of safety and efficacy profiles for CALAA-01 in humans."
Source: Datamonitor
Related Articles
- PCI Biotech-led Consortium Awarded EUR1.1 m Eurostars Grant for siRNA
- Calando Announces Development of Second siRNA Cancer Drug
- Calando Pharmaceuticals Announces Next siRNA Therapeutic Candidate for Oncology
- Arrowhead Nanobiotechnology Subsidiaries, Calando Pharmaceuticals and Insert Therapeutics, Complete Merger
- Calando Granted Approval to Initiate Phase I Trial of Anti-Cancer Drug
- Calando Receives FDA Approval for Phase I Clinical Trial Using a Targeted siRNA Nanoparticle Therapeutic
- Calando Files IND for siRNA Nanoparticle Therapeutic in Oncology
- Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
- Newly Published Results Demonstrate Potential of Arrowhead Subsidiary's Technology As a New Tool in Fight Against Cancer
- YM BioSciences to Present Results of Norelin(TM) Study at Cancer Vaccines/Adjuvants/Delivery 2005 Congress in Lisbon
 |
 |
User Comments (0)
RSS Feeds